KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments (2021 - 2023)

Recursion Pharmaceuticals' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $480000.0 for Q3 2023.

  • For Q3 2023, Change in Acquisitions & Divestments fell 99.22% year-over-year to $480000.0; the TTM value through Dec 2024 reached $480000.0, changed 0.0%, while the annual FY2023 figure was $480000.0, 99.79% down from the prior year.
  • Change in Acquisitions & Divestments reached $480000.0 in Q3 2023 per RXRX's latest filing, down from $61.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $147.6 million in Q1 2022 to a low of $480000.0 in Q3 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $60.1 million, with a median of $61.5 million recorded in 2022.
  • The largest YoY upside for Change in Acquisitions & Divestments was 99.22% in 2023 against a maximum downside of 99.22% in 2023.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $69.2 million in 2021, then dropped by 11.05% to $61.5 million in 2022, then plummeted by 99.22% to $480000.0 in 2023.
  • Per Business Quant, the three most recent readings for RXRX's Change in Acquisitions & Divestments are $480000.0 (Q3 2023), $61.5 million (Q3 2022), and $21.4 million (Q2 2022).